Literature DB >> 15507627

Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo.

Jennifer Moffat1, Chengjun Mo, Jason J Cheng, Marvin Sommer, Leigh Zerboni, Shaye Stamatis, Ann M Arvin.   

Abstract

Varicella-zoster virus (VZV) glycoprotein E (gE) is essential for VZV replication. To further analyze the functions of gE in VZV replication, a full deletion and point mutations were made in the 62-amino-acid (aa) C-terminal domain. Targeted mutations were introduced in YAGL (aa 582 to 585), which mediates gE endocytosis, AYRV (aa 568 to 571), which targets gE to the trans-Golgi network (TGN), and SSTT, an "acid cluster" comprising a phosphorylation motif (aa 588 to 601). Substitutions Y582G in YAGL, Y569A in AYRV, and S593A, S595A, T596A, and T598A in SSTT were introduced into the viral genome by using VZV cosmids. These experiments demonstrated a hierarchy in the contributions of these C-terminal motifs to VZV replication and virulence. Deletion of the gE C terminus and mutation of YAGL were lethal for VZV replication in vitro. Mutations of AYRV and SSTT were compatible with recovery of VZV, but the AYRV mutation resulted in rapid virus spread in vitro and the SSTT mutation resulted in higher virus titers than were observed for the parental rOka strain. When the rOka-gE-AYRV and rOka-gE-SSTT mutants were evaluated in skin and T-cell xenografts in SCIDhu mice, interference with TGN targeting was associated with substantial attenuation, especially in skin, whereas the SSTT mutation did not alter VZV infectivity in vivo. These results provide the first information about how targeted mutations of this essential VZV glycoprotein affect viral replication in vitro and VZV virulence in dermal and epidermal cells and T cells within intact tissue microenvironments in vivo.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507627      PMCID: PMC525039          DOI: 10.1128/JVI.78.22.12406-12415.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers.

Authors:  Chia-Chi Ku; Jorge A Padilla; Charles Grose; Eugene C Butcher; Ann M Arvin
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus.

Authors:  M H Sommer; E Zagha; O K Serrano; C C Ku; L Zerboni; A Baiker; R Santos; M Spengler; J Lynch; C Grose; W Ruyechan; J Hay; A M Arvin
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

3.  Varicella-zoster Virus gB and gE coexpression, but not gB or gE alone, leads to abundant fusion and syncytium formation equivalent to those from gH and gL coexpression.

Authors:  L Maresova; T J Pasieka; C Grose
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells.

Authors:  Jennifer Moffat; Hideki Ito; Marvin Sommer; Shannon Taylor; Ann M Arvin
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  The immediate-early 63 protein of Varicella-Zoster virus: analysis of functional domains required for replication in vitro and for T-cell and skin tropism in the SCIDhu model in vivo.

Authors:  Armin Baiker; Christoph Bagowski; Hideki Ito; Marvin Sommer; Leigh Zerboni; Klaus Fabel; John Hay; William Ruyechan; Ann M Arvin
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  Phosphorylation by the varicella-zoster virus ORF47 protein serine kinase determines whether endocytosed viral gE traffics to the trans-Golgi network or recycles to the cell membrane.

Authors:  T K Kenyon; Jeffrey I Cohen; Charles Grose
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

Review 7.  Membrane fusion mediated by herpesvirus glycoproteins: the paradigm of varicella-zoster virus.

Authors:  Nancy L Cole; Charles Grose
Journal:  Rev Med Virol       Date:  2003 Jul-Aug       Impact factor: 6.989

8.  The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells.

Authors:  Chengjun Mo; Jay Lee; Marvin Sommer; Charles Grose; Ann M Arvin
Journal:  Virology       Date:  2002-12-20       Impact factor: 3.616

9.  Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo.

Authors:  Hideki Ito; Marvin H Sommer; Leigh Zerboni; Hongying He; Dwayne Boucaud; John Hay; William Ruyechan; Ann M Arvin
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo.

Authors:  Bunji Sato; Hideki Ito; Stewart Hinchliffe; Marvin H Sommer; Leigh Zerboni; Ann M Arvin
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

View more
  33 in total

1.  Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection.

Authors:  Barbara Berarducci; Minako Ikoma; Shaye Stamatis; Marvin Sommer; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 2.  Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model.

Authors:  Chia-Chi Ku; Jaya Besser; Allison Abendroth; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

3.  Packaging determinants in the UL11 tegument protein of herpes simplex virus type 1.

Authors:  Joshua S Loomis; Richard J Courtney; John W Wills
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

4.  Incorporation of three endocytosed varicella-zoster virus glycoproteins, gE, gH, and gB, into the virion envelope.

Authors:  Lucie Maresova; Tracy Jo Pasieka; Elizabeth Homan; Erick Gerday; Charles Grose
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Virion incorporation of the herpes simplex virus type 1 tegument protein VP22 occurs via glycoprotein E-specific recruitment to the late secretory pathway.

Authors:  Julianna Stylianou; Kevin Maringer; Rachelle Cook; Emmanuelle Bernard; Gillian Elliott
Journal:  J Virol       Date:  2009-03-11       Impact factor: 5.103

6.  The C-terminus of varicella-zoster virus glycoprotein M contains trafficking motifs that mediate skin virulence in the SCID-human model of VZV pathogenesis.

Authors:  Leigh Zerboni; Phillip Sung; Marvin Sommer; Ann Arvin
Journal:  Virology       Date:  2018-08-14       Impact factor: 3.616

7.  Optimal replication of human cytomegalovirus correlates with endocytosis of glycoprotein gpUL132.

Authors:  Barbara Kropff; Yvonne Koedel; William Britt; Michael Mach
Journal:  J Virol       Date:  2010-05-05       Impact factor: 5.103

Review 8.  Molecular mechanisms of varicella zoster virus pathogenesis.

Authors:  Leigh Zerboni; Nandini Sen; Stefan L Oliver; Ann M Arvin
Journal:  Nat Rev Microbiol       Date:  2014-02-10       Impact factor: 60.633

9.  The insulin degrading enzyme binding domain of varicella-zoster virus (VZV) glycoprotein E is important for cell-to-cell spread and VZV infectivity, while a glycoprotein I binding domain is essential for infection.

Authors:  Mir A Ali; Qingxue Li; Elizabeth R Fischer; Jeffrey I Cohen
Journal:  Virology       Date:  2009-02-23       Impact factor: 3.616

10.  Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection.

Authors:  Barbara Berarducci; Jaya Rajamani; Leigh Zerboni; Xibing Che; Marvin Sommer; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.